San Diego based DexCom (DXCM), a player in the self-monitoring of blood glucose (SMBG) business, designs and manufactures continuous glucose monitoring (CGM) systems for use by diabetes patients and healthcare providers in hospitals. The continuous glucose monitoring market in the United States is likely to grow at an impressive CAGR of around 14.2% during 2010-2015, reports RNCOS.
Self-monitoring of blood glucose is now playing an important role in the treatment of diabetes mellitus. With an increasing number of patients using SMBG devices, the market for SMBG devices is about $4.5 billion worth of sales, primarily spread among only three companies - Abbott (ABT), Medtronic (MDT) and DexCom. In this article...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: